The Best of LacertaBio.com 2015
So, how did we do? This year, our fifth, was very good. By all objective measures, 2015 was our most successful year, and we want to thank all…
Menu
Comments on Biotech Showcase Webinar
This morning, our friends at EBD and MacDougall Biomedical Communications presented a very good webinar on preparing for the upcoming festivities in San Francisco. In case you missed it, I…
Skyrocketing Prices for Dermatology Rx Products
Last week, a study published in JAMA Dermatology examined the skyrocketing prices for dermatology prescription products. Amazingly, Of the 19 brand-name drugs analyzed, the retail prices of 7 drugs more…
#BEU15 Wrap Up: Churches, Football, and Meetings
I love what you did with the place... It's always difficult for us to contribute any sensible overarching overview of any partnering conference, especially BIO Europe Fall. This is entirely…
License-Ability Analysis Helps Focus BD Efforts
We go to a lot of conferences. And, as a result, we see a lot of assets being marketed by pharma & biotech executives which will likely never find a…
Comments on EBD Partnering Analysis #BEU15
Last month, EBD and IMS partnered to analyze meeting outcomes from four conferences, covering nearly 5,000 participating companies. Their report is available here (PDF). As we are knee-deep in scheduling…
Postcards from Bangalore
Last week, we had the good fortune of spending a week in India, along with our colleagues from Ventac Partners. Our trip took us through the cities of Mumbai,…
Would Mefloquine Be Approved Today?
As part of my preparations for an upcoming trip to India, my physician prescribed a 6-week prophylactic course of mefloquine to prevent malaria. The weekly dosing schedule prompted me to…
Licensing or Acquiring Assets from Big Pharma
Michael Gilman, CEO of Padlock Therapeutics, wrote a terrific post recounting his experiences from in-licensing assets from Big Pharma. Mike's perspective is unique in that he has managed to…
Global Formulation Report
The July/August issue of Drug Development and Delivery has an extensive report on the business and science of formulation and drug delivery. The report is based on the data…
- Go to the previous page
- 1
- …
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- …
- 33
- Go to the next page